Daniel Cochrane

664 total citations
9 papers, 545 citations indexed

About

Daniel Cochrane is a scholar working on Epidemiology, Genetics and Biotechnology. According to data from OpenAlex, Daniel Cochrane has authored 9 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Epidemiology, 3 papers in Genetics and 3 papers in Biotechnology. Recurrent topics in Daniel Cochrane's work include Virus-based gene therapy research (3 papers), Cancer Research and Treatments (3 papers) and Cytomegalovirus and herpesvirus research (3 papers). Daniel Cochrane is often cited by papers focused on Virus-based gene therapy research (3 papers), Cancer Research and Treatments (3 papers) and Cytomegalovirus and herpesvirus research (3 papers). Daniel Cochrane collaborates with scholars based in United Kingdom, United States and Croatia. Daniel Cochrane's co-authors include Meera G. Nair, Judith E. Allen, Carole Rickards, Gavin W. G. Wilkinson, Virginie Prod’homme, Richard J. Stanton, Peter Tomašec, Rebecca Aicheler, Brian P. McSharry and Sian Llewellyn‐Lacey and has published in prestigious journals such as Proceedings of the National Academy of Sciences, European Journal of Cancer and Journal of General Virology.

In The Last Decade

Daniel Cochrane

9 papers receiving 534 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Cochrane United Kingdom 6 322 273 98 76 69 9 545
Delbert S. Abi Abdallah United States 8 464 1.4× 197 0.7× 154 1.6× 64 0.8× 116 1.7× 10 658
Rodrigo P. Soares Brazil 8 368 1.1× 227 0.8× 96 1.0× 59 0.8× 96 1.4× 9 610
Keith Bouchard United States 10 786 2.4× 229 0.8× 67 0.7× 162 2.1× 100 1.4× 12 1.0k
Stacie Reckling United States 9 628 2.0× 227 0.8× 85 0.9× 94 1.2× 46 0.7× 14 878
Suzanne Cole United States 11 285 0.9× 359 1.3× 31 0.3× 158 2.1× 103 1.5× 13 825
Sara Botto United States 11 214 0.7× 282 1.0× 44 0.4× 137 1.8× 118 1.7× 16 511
Ronald B. Smeltz United States 13 383 1.2× 98 0.4× 66 0.7× 65 0.9× 102 1.5× 19 567
T. Sprong Netherlands 9 343 1.1× 81 0.3× 198 2.0× 142 1.9× 76 1.1× 14 646
Senta M. Walton Switzerland 17 749 2.3× 473 1.7× 49 0.5× 92 1.2× 81 1.2× 20 1.0k
Alain Gumy Switzerland 7 582 1.8× 209 0.8× 51 0.5× 47 0.6× 40 0.6× 8 806

Countries citing papers authored by Daniel Cochrane

Since Specialization
Citations

This map shows the geographic impact of Daniel Cochrane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Cochrane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Cochrane more than expected).

Fields of papers citing papers by Daniel Cochrane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Cochrane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Cochrane. The network helps show where Daniel Cochrane may publish in the future.

Co-authorship network of co-authors of Daniel Cochrane

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Cochrane. A scholar is included among the top collaborators of Daniel Cochrane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Cochrane. Daniel Cochrane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Bentley, Kirsten, Isa Murrell, Ceri A. Fielding, et al.. (2025). Virion proteomics of genetically intact HCMV reveals a regulator of envelope glycoprotein composition that protects against humoral immunity. Proceedings of the National Academy of Sciences. 122(38). e2425622122–e2425622122. 2 indexed citations
2.
Cochrane, Daniel, et al.. (2021). Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells. International Journal of Infectious Diseases. 113. 155–161. 32 indexed citations
3.
Francini, Nora, Daniel Cochrane, Giuseppe Mantovani, et al.. (2019). Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity In Vitro and In Vivo. Bioconjugate Chemistry. 30(4). 1244–1257. 19 indexed citations
4.
Calderón, Hugo, et al.. (2014). Evaluation of Enadenotucirev (ColoAd1), an oncolytic Ad11/Ad3 chimeric group B adenovirus, in combination with chemotherapeutic agents in a murine model of ovarian cancer. Human Gene Therapy. 25. 1 indexed citations
5.
Champion, Brian, et al.. (2014). 117 “Arming” the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours. European Journal of Cancer. 50. 41–41. 1 indexed citations
6.
Prod’homme, Virginie, Daniel Sugrue, Richard J. Stanton, et al.. (2010). Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. Journal of General Virology. 91(8). 2034–2039. 89 indexed citations
7.
Wilkinson, Gavin W. G., Peter Tomašec, Richard J. Stanton, et al.. (2008). Modulation of natural killer cells by human cytomegalovirus. Journal of Clinical Virology. 41(3). 206–212. 192 indexed citations
8.
Tasker, L, et al.. (2008). Infection of mice with respiratory syncytial virus during neonatal life primes for enhanced antibody and T cell responses on secondary challenge. Clinical & Experimental Immunology. 153(2). 277–288. 29 indexed citations
9.
Nair, Meera G., Daniel Cochrane, & Judith E. Allen. (2003). Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. Immunology Letters. 85(2). 173–180. 180 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Delbert S. Abi Abdallah Breakdown of academic impact, for papers by Rodrigo P. Soares Breakdown of academic impact, for papers by Keith Bouchard Breakdown of academic impact, for papers by Stacie Reckling Breakdown of academic impact, for papers by Suzanne Cole Breakdown of academic impact, for papers by Sara Botto Breakdown of academic impact, for papers by Ronald B. Smeltz Breakdown of academic impact, for papers by T. Sprong Breakdown of academic impact, for papers by Senta M. Walton Breakdown of academic impact, for papers by Alain Gumy
Rankless by CCL
2026